Clinical and economic burden of systemic lupus erythematosus in Colombia

Gihan Hamdy Elsisi, Gerardo Quintana, Diana Gil, Pedro Santos, Diana Fernandez

Research output: Contribution to journalArticlepeer-review


AIMS: Our cost-of-illness (COI) model adopted payer and societal perspectives over five years to measure the economic burden of Systemic Lupus Erythematosus (SLE) in Colombia.

MATERIALS AND METHODS: A prevalence-based model was constructed to estimate costs and economic consequences for SLE patients in Colombia. The model included four health states: three phenotypes of SLE representing mild, moderate, and severe states and death. The clinical inputs were captured from the published literature and validated by the Delphi panel. Our model measured direct medical and indirect costs, including disease management, transient events, and indirect costs. One-way sensitivity analysis was also performed.

RESULTS: The number of Colombian SLE patients was 37,498. The number of SLE patients with mild, moderate, and severe phenotypes was 5343, 28757 and 3,397, respectively. SLE-patients with moderate (Colombian pesos; COP 146 billion) and severe phenotypes (COP276 billion) incurred higher costs than those with mild phenotypes (COP2 billion), over 5 years. The total SLE cost in Colombia over five years from the payer and societal perspectives was estimated to be COP 915 billion and 8 trillion, respectively. The costs per patient per year from the payer and societal perspectives were COP 4,881,902 ($3,510) and COP 46,637,054 ($33,528), respectively.

CONCLUSION: The burden of SLE in Colombia over five years is substantially high, mainly due to the consequences of economic loss because it affects women and men of working age, in addition to the costs of SLE management and its consequences, such as flares, infection, and organ damage. Our COI indicated that disease management costs among patients with moderate and severe SLE were substantially higher than those among patients with a mild phenotype. Therefore, more attention should be paid to limiting the progression of SLE and the occurrence of flares, with the need for further economic evaluation of novel treatment strategies that help in disease control.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of medical economics
Issue numbersup1
StatePublished - 2024
Externally publishedYes


  • Male
  • Humans
  • Female
  • Health Care Costs
  • Colombia/epidemiology
  • Financial Stress
  • Lupus Erythematosus, Systemic
  • Cost of Illness


Dive into the research topics of 'Clinical and economic burden of systemic lupus erythematosus in Colombia'. Together they form a unique fingerprint.

Cite this